EXCLUSIVE: Moderna Spokesperson Tells Benzinga "Moderna Disagrees With The Decision Of The European Patent Office Regarding The '565 Patent. We Continue To Believe In The Strength And Validity Of The '565 Patent And Will Appeal This Decision"
Portfolio Pulse from Benzinga Newsdesk
A spokesperson from Moderna has expressed disagreement with the European Patent Office's decision regarding the '565 patent. Moderna maintains confidence in the strength and validity of the patent and plans to appeal the decision.
November 21, 2023 | 3:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Moderna's intention to appeal the European Patent Office's decision on the '565 patent reflects its commitment to defending its intellectual property, which could have implications for its future revenue and market position.
The news indicates a legal challenge that Moderna is willing to undertake, which shows the company's proactive stance in protecting its patents. However, the outcome of the appeal is uncertain, and until a resolution is reached, the impact on the stock is likely to be neutral with potential for future volatility.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80